GlassScriptPhysician profile
Harry Hamburger
NPI 1396834883
$1,375.53
in general payments reported to CMS, 2019-2025
14 companies · $63.93 in 2025
The $63.93 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $255 · 2021: $515 · 2022: $236 · 2023: $188 · 2024: $117 · 2025: $63.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $369.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $369.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $373.02 | 2022-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $209.85 | 2020-2021 | |
| Horizon Therapeutics Plc | $153.29 | 2021-2022 | |
| Kala Pharmaceuticals, INC. | $117.56 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $102.83 | 2021-2024 | Acthar |
| Aerie Pharmaceuticals, INC. | $86.94 | 2020-2021 | |
| Eyevance Pharmaceuticals LLC | $72.64 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $68.27 | 2020-2021 | |
| Dompe US, INC. | $48.51 | 2021 | |
| Alcon Vision LLC | $42.86 | 2022 | |
| Sun Pharmaceutical Industries INC. | $42.47 | 2020 | |
| Rxsight INC | $21.53 | 2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece |
| Ocular Therapeutix, INC. | $19.86 | 2021 | |
| Biotissue Holdings INC. | $15.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harry Hamburger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.